This article is more than 5 years old. Information may no longer be current.
VIDEO: Flibanserin may be effective treatment for hypoactive sexual desire disorder in postmenopausal women
PHILADELPHIA — In this video exclusive, Sheryl A. Kingsberg, PhD, president-elect of the North American Society, discusses data showing flibanserin may be safe and effective for treatment of hypoactive sexual desire disorder in postmenopausal women.
Currently, flibanserin (Addyi, Valeant Pharmaceuticals) is the only approved therapy for hypoactive sexual desire disorder but is only indicated for use in premenopausal women.
According to Kingsberg, hypoactive sexual desire disorder is the most prevalent sexual dysfunction of women of all ages, but the highest rates are among postmenopausal women.
Data being presented by Kingsberg revealed that flibanserin was more effective than placebo in improving not only the desire domain on the Female Sexual Function Index, as previously reported by results from the Snow Drop Trial, but also improves all domains related to sexual function.